Open AccessAcute Lower Back Pain after Intralesional Injection of Collagenase Clostridium histolyticum for Peyronie’s Disease
Author(s) -
John T. Sigalos,
Michelle K Li,
Dar A. Yoffe,
Neilufar Modiri,
Mingyi Hu,
Dyvon Walker,
Thomas W. Gaither,
Alvaro Santamaria,
K. Regets,
Sriram Eleswarapu,
Jesse N. Mills
Publication year - 2022
Publication title -
the journal of urology/the journal of urology
Language(s) - English
Resource type - Journals
eISSN - 1527-3792
pISSN - 0022-5347
DOI - 10.1097/ju.0000000000002789
Subject(s) - medicine , incidence (geometry) , adverse effect , back pain , surgery , peyronie's disease , retrospective cohort study , disease , physics , alternative medicine , pathology , optics
The safety label for collagenase Clostridium histolyticum was updated to include postinjection acute lower back pain as an adverse event observed with intralesional therapy for Peyronie's disease. Incidence and causality are unknown. We assessed frequencies and temporal associations for this adverse event in a large cohort.